focus on Golgi glyco-oncogenes

Unraveling the Secrets of Golgi Glyco-Oncogenes
for Innovative Anticancer Therapies.

Meet the team

PROFILE

Startup Innovating Golgi-Based Glycan Biosynthesis Technologies

Golgenia is a startup that develops know-how and new technologies in the field of Golgi-based glycan biosynthesis (or glycosylation), a relatively unexplored territory, to generate new therapeutic approaches. Golgenia has discovered that some Golgi-based proteins can cause tumors by inducing errors and imbalances in the glycosylation process. These are defined glyco-oncogenes. Glyco-oncogenes are relatively numerous and represent a new research platform for the development of anticancer drugs.

Our Mission

Scientific Idea

Click to see more
To discover, characterize and inhibit Golgi glyco-oncogenes as a means to impede the production of aberrant glycans involved in tumorigenesis.

Data

Click to see more
Golgenia's scientists have identified and tested in cellular and animal models a large set of glyco-oncogenes, and developed a first series of inhibitors directed against a specific glyco-oncogenes cluster acting in glycosphingolipid synthesis.

Patents

Click to see more
Golgenia patented a series of compounds that inhibit a group of glyco-oncogenes for the treatment of a specific set of solid tumors.

Clinical Tests

Click to see more
Clinical testing of these inhibitors is planned to start in 2024 in collaboration with established pharma industries and research organizations.

Therapeutic agents

Click to see more
Golgenia patented a series of compounds that inhibit a group of glyco-oncogenes for the treatment of a specific set of solid tumors.

Our Mission

Scientific Idea

To discover, characterize and inhibit Golgi glyco-oncogenes as a means to impede the production of aberrant glycans involved in tumorigenesis.

Data

Golgenia's scientists have identified and tested in cellular and animal models a large set of glyco-oncogenes, and developed a first series of inhibitors directed against a specific glyco-oncogenes cluster acting in glycosphingolipid synthesis.

Patents

Golgenia patented a series of compounds that inhibit a group of glyco-oncogenes for the treatment of a specific set of solid tumors.

Clinical Tests

Clinical testing of these inhibitors is planned to start in 2024 in collaboration with established pharma industries and research organizations.

Therapeutic agents

Golgenia patented a series of compounds that inhibit a group of glyco-oncogenes for the treatment of a specific set of solid tumors.

Our Mission

Scientific Idea

Click to see more
To discover, characterize and inhibit Golgi glyco-oncogenes as a means to impede the production of aberrant glycans involved in tumorigenesis.

Data

Click to see more
Golgenia's scientists have identified and tested in cellular and animal models a large set of glyco-oncogenes, and developed a first series of inhibitors directed against a specific glyco-oncogenes cluster acting in glycosphingolipid synthesis.

Patents

Click to see more
Golgenia patented a series of compounds that inhibit a group of glyco-oncogenes for the treatment of a specific set of solid tumors.

Clinical Tests

Click to see more
Clinical testing of these inhibitors is planned to start in 2024 in collaboration with established pharma industries and research organizations.

Therapeutic agents

Click to see more
Golgenia patented a series of compounds that inhibit a group of glyco-oncogenes for the treatment of a specific set of solid tumors.

IMPACT

The Golgi glyco-oncogenes

Glycans are abundant sugar polymers acting in a myriad of cellular functions and pathological conditions. They are synthesized mostly in the Golgi complex (an organelle called the “cellular glycosylation factory”) by hundreds of glycosylation enzymes and accessory molecules. The glyco-oncogenes are a group of Golgi-based proteins endowed with oncogenic properties that have been recently uncovered by Golgenia. The glyco-oncogenes act by perturbing glycosylation, causing the formation of aberrant glycans, which then lead to tumour development.

IMPACT

Impact in cancer therapy

Current therapeutic approaches in glyco-biology target the aberrant tumorigenic glycans produced by the glyco- oncogenes, rather the glyco-oncogenes themselves. Driven by the proven efficacy of drugs that inhibit oncogenes in anticancer therapy, Golgenia and collaborators have leveraged their knowledge of Golgi glycosylation to develop direct inhibitors of the glyco-oncogenes. Golgenia’s first drugs target glyco-oncogenes that alter glycan synthesis on lipid scaffolds. These new drugs open up new therapeutic possibilities for a large number of cancer patients.

By Camillo Golgi

CONTACT US

Unlocking New Horizons with Golgenia

Connect with us and discover how Golgenia’s  research on Golgi Glyco-Oncogenes is contributing to the future of cancer treatment.

contact us
Torna in alto